Centric Wealth Management Purchases Shares of 16,847 Caribou Biosciences, Inc. (NASDAQ:CRBU)

Centric Wealth Management acquired a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 16,847 shares of the company’s stock, valued at approximately $27,000.

Several other hedge funds also recently modified their holdings of CRBU. Erste Asset Management GmbH bought a new stake in Caribou Biosciences during the 3rd quarter worth approximately $28,000. Diametric Capital LP bought a new stake in shares of Caribou Biosciences during the fourth quarter worth $42,000. US Bancorp DE increased its stake in shares of Caribou Biosciences by 3,524.2% in the fourth quarter. US Bancorp DE now owns 27,218 shares of the company’s stock valued at $43,000 after buying an additional 26,467 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Caribou Biosciences in the third quarter valued at about $43,000. Finally, Thrive Wealth Management LLC acquired a new position in Caribou Biosciences during the 4th quarter worth about $51,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CRBU shares. Bank of America lowered their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research report on Wednesday, March 19th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $10.33.

Caribou Biosciences Stock Down 2.8 %

Shares of Caribou Biosciences stock opened at $0.91 on Tuesday. Caribou Biosciences, Inc. has a 12 month low of $0.88 and a 12 month high of $5.15. The business has a fifty day simple moving average of $1.22 and a 200 day simple moving average of $1.70. The stock has a market cap of $84.92 million, a PE ratio of -0.55 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.08 million during the quarter, compared to analysts’ expectations of $2.11 million. Analysts expect that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.